Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q3 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $390 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.